Pharming B.V.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Pharming B.V.
Live alerts from global media, monitored by Business Radar
2024-05-09 (ceo.ca)
Pharming Group reports first quarter 2024 financial results and provides business update, by @GlobeNewswire
Leiden, the Netherlands, May 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the three months ended March 31, 2024.
Read more
2024-05-09 (ceo.ca)
Pharming Group reports first quarter 2024 financial results and provides business update, by @GlobeNewswire
Leiden, the Netherlands, May 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the three months ended March 31, 2024.
Read more
2024-04-06 (finanznachrichten.de)
Pharming Group N.V.: Pharming Group to report first quarter 2024 financial results on May 8
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results
Read more
2024-04-06 (finanznachrichten.de)
Pharming Group N.V.: Pharming Group to report first quarter 2024 financial results on May 8
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results
Read more
2023-10-12 (yahoo.com)
Pharming Group to report third quarter 2023 financial results on October 26
Leiden, The Netherlands, October 12, 2023: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2023 financial results, for the period ended September 30, on Thursday, October 26, 2023.
Read more
2009-02-13 (businessinsider.nl)
Pharming's loss increased to 26 million
The company expects the first two milestone payments of 10 million euros this year from partner Aslan, for the development of the drug lactoferrin,
Read more